相关实验视频
Updated: Jan 10, 2026

05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
7.3K
在降低心血管风险方面,GLP-1受体激活剂和SGLT2抑制剂的互补但不同的作用
Nóra Homoródi1, Éva Varga2, Zoltán Szabó3
1Department of Cardiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Biomedicines
|November 27, 2025
概括
新型抗糖尿病药物,葡萄糖样-1 (GLP-1) 受体激活剂和-葡萄糖共运输体2 (SGLT2) 抑制剂,提供心血管方面的好处. 本综述比较了它们的机制,疗效和安全性,以指导2型糖尿病管理的临床决策.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 最近抗糖尿病药物的进展显著影响了2型糖尿病 (T2DM) 治疗和心血管 (CV) 风险降低策略.
- 葡萄糖类-1 (GLP-1) 受体激动剂和-葡萄糖共运输体2 (SGLT2) 抑制剂是具有证明心脏病益处的关键新型药物类.
研究的目的:
- 提供基于文献的GLP-1受体激动剂和SGLT2抑制剂的比较总结.
- 阐明它们的作用机制,心血管风险降低功效和安全性.
- 确定影响临床决策的因素,以确定它们在T2DM患者中的使用情况.
主要方法:
- 关于GLP-1受体激动剂和SGLT2抑制剂的综合文献综述.
- 对它们的药理作用和临床结果进行比较分析.
- 综合安全数据和不良影响概况.
主要成果:
- GLP-1受体激动剂通过改善内皮功能,减少炎症和斑块稳定,产生抗动脉样硬化作用.
- SGLT2 抑制剂通过包括自然尿,降低血体积和增强体利用等机制提供心血管保护.
- 这两种药物类别都具有明显但显著的心血管优势,特别考虑副作用和潜在的组合疗法.
结论:
- GLP-1受体激动剂和SGLT2抑制剂代表了管理T2DM和降低心血管风险的独特治疗途径.
- 了解它们的个体机制,疗效和安全性,对于优化患者护理和指导药物选择至关重要.
- 需要进一步的研究来探索最佳组合策略,并完善临床决策算法.
相关概念视频
Glucagon-like Receptor Agonists
824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
Oral Hypoglycemic Agents: Biguanides and Glitazones
567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566
Oral Hypoglycemic Agents: Glinides
573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573
Glucose Transporters
27.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.1K
